Literature DB >> 29224680

Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome.

Rebecca Fischer-Betz1, Christof Specker2.   

Abstract

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with a high prevalence in females of childbearing age. Pregnancy in SLE nowadays has favorable outcomes for the majority of women. However, flares of disease activity, preeclampsia, fetal loss, and preterm birth are well-known risks in such pregnancies. Anti-SS-A(Ro)/SS-B(La) antibodies put fetuses at risk for congenital heart block and neonatal lupus. Several risk factors for adverse pregnancy outcomes have been identified. Women with antiphospholipid antibodies or antiphospholipid syndrome and lupus nephritis represent a group with high risk for obstetric complications. Factors such as appropriate preconception counseling and medication adjustment, strict disease control prior to pregnancy, and intensive surveillance during and after pregnancy are essential to improve pregnancy outcome. The aim of this review article is to update on the medical care of pregnancy in these women to ensure the best maternal and fetal prognosis.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiphospholipid syndrome; Fetal loss; Neonatal lupus syndrome; Preeclampsia; Pregnancy; Systemic lupus erythematosus

Mesh:

Year:  2017        PMID: 29224680     DOI: 10.1016/j.berh.2017.09.011

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  21 in total

Review 1.  The role of Th17 cells in the pathophysiology of pregnancy and perinatal mood and anxiety disorders.

Authors:  Lauren M Osborne; Amitoj Brar; Sabra L Klein
Journal:  Brain Behav Immun       Date:  2018-11-19       Impact factor: 7.217

2.  All-cause hospitalizations in systemic lupus erythematosus from a single medical center in Israel.

Authors:  Ofer Levy; Andrey Markov; Yulia Drob; Ilia Maslakov; Moshe Tishler; Mirit Amit-Vazina
Journal:  Rheumatol Int       Date:  2018-08-27       Impact factor: 2.631

3.  Pr-AKI: Acute Kidney Injury in Pregnancy - Etiology, Diagnostic Workup, Management.

Authors:  Florian G Scurt; Ronnie Morgenroth; Katrin Bose; Peter R Mertens; Christos Chatzikyrkou
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-03-03       Impact factor: 2.915

Review 4.  Rheumatic Diseases in Reproductive Age-the Possibilities and the Risks.

Authors:  Bogna Grygiel-Górniak; Elena Masiero; Briana Candace Nevaneeth; Melissa Mary Jojy
Journal:  Reprod Sci       Date:  2022-03-31       Impact factor: 3.060

5.  Expression of lncRNA NEAT1 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus and its correlation with Th1/Th2 balance.

Authors:  Yanni Jiang; Yi Zhao; Xianming Mo
Journal:  Int J Clin Exp Pathol       Date:  2021-05-15

6.  [Antiphospholipid syndrome : Update on diagnostics and management].

Authors:  Christof Specker; Rebecca Fischer-Betz; Thomas Dörner
Journal:  Z Rheumatol       Date:  2020-04       Impact factor: 1.372

7.  Effectiveness of reproductive health counseling of women with systemic lupus erythematosus: observational cross-sectional study at an academic lupus clinic.

Authors:  Luisa Brites; Stefanie Silva; Laura Andreoli; Luis Inês
Journal:  Rheumatol Int       Date:  2020-08-07       Impact factor: 2.631

Review 8.  Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations.

Authors:  Yang Mao-Draayer; Sandra Thiel; Elizabeth A Mills; Tanuja Chitnis; Michelle Fabian; Ilana Katz Sand; M Isabel Leite; Sven Jarius; Kerstin Hellwig
Journal:  Nat Rev Neurol       Date:  2020-02-20       Impact factor: 42.937

9.  [Pregnancy and rheumatic diseases].

Authors:  R Fischer-Betz; S Späthling-Mestekemper
Journal:  Z Rheumatol       Date:  2020-02       Impact factor: 1.372

Review 10.  Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies.

Authors:  Marilyn E Allen; Violeta Rus; Gregory L Szeto
Journal:  Trends Mol Med       Date:  2020-10-09       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.